Abbott Laboratories (NYSE:ABT) insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total value of $9,729,225.00. Following the sale, the insider now directly owns 221,488 shares in the company, valued at approximately $10,963,656. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Abbott Laboratories (ABT) traded down 1.12% during trading on Friday, hitting $48.74. The stock had a trading volume of 4,810,807 shares. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $51.13. The firm’s 50-day moving average is $49.15 and its 200 day moving average is $45.90. The firm has a market cap of $84.68 billion, a price-to-earnings ratio of 68.26 and a beta of 1.07.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.55 earnings per share. On average, analysts expect that Abbott Laboratories will post $2.49 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th were paid a dividend of $0.265 per share. The ex-dividend date was Wednesday, July 12th. This represents a $1.06 annualized dividend and a yield of 2.17%. Abbott Laboratories’s dividend payout ratio (DPR) is 149.30%.

ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/18/abbott-laboratories-abt-insider-sells-9729225-00-in-stock.html.

Several brokerages recently issued reports on ABT. Cowen and Company reissued a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research note on Thursday. Citigroup Inc. began coverage on Abbott Laboratories in a research note on Thursday. They set a “neutral” rating and a $53.00 target price on the stock. BidaskClub downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, August 6th. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Guggenheim began coverage on Abbott Laboratories in a research note on Thursday, June 29th. They issued a “buy” rating and a $58.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $52.14.

Large investors have recently bought and sold shares of the company. Raymond James Trust N.A. boosted its stake in Abbott Laboratories by 6.5% in the first quarter. Raymond James Trust N.A. now owns 163,719 shares of the healthcare product maker’s stock valued at $7,270,000 after buying an additional 9,960 shares during the period. Nadler Financial Group Inc. boosted its stake in Abbott Laboratories by 3.4% in the first quarter. Nadler Financial Group Inc. now owns 11,823 shares of the healthcare product maker’s stock valued at $525,000 after buying an additional 393 shares during the period. Cordasco Financial Network boosted its stake in Abbott Laboratories by 175.8% in the first quarter. Cordasco Financial Network now owns 5,516 shares of the healthcare product maker’s stock valued at $245,000 after buying an additional 3,516 shares during the period. Stock Yards Bank & Trust Co. boosted its stake in Abbott Laboratories by 366.2% in the first quarter. Stock Yards Bank & Trust Co. now owns 195,845 shares of the healthcare product maker’s stock valued at $8,698,000 after buying an additional 153,836 shares during the period. Finally, Chesley Taft & Associates LLC boosted its stake in Abbott Laboratories by 0.5% in the first quarter. Chesley Taft & Associates LLC now owns 343,785 shares of the healthcare product maker’s stock valued at $15,267,000 after buying an additional 1,592 shares during the period. 70.86% of the stock is owned by institutional investors.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.